These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 15854875)

  • 1. Is population-level perversity a likely outcome of mass vaccination against HIV?
    Bogaards JA; van Ballegooijen WM; Jan Weverling G; Boerlijst MC; Goudsmit J
    Lancet Infect Dis; 2005 May; 5(5):254; author reply 255-6. PubMed ID: 15854875
    [No Abstract]   [Full Text] [Related]  

  • 2. Could disease-modifying HIV vaccines cause population-level perversity?
    Smith RJ; Blower SM
    Lancet Infect Dis; 2004 Oct; 4(10):636-9. PubMed ID: 15451492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV vaccines.
    Ellenberg SS; Rida WN
    Lancet; 1997 Feb; 349(9048):361. PubMed ID: 9024406
    [No Abstract]   [Full Text] [Related]  

  • 4. A relative standard for minimal risk is unnecessary and potentially harmful to children: lessons from the Phambili trial.
    Nelson RM
    Am J Bioeth; 2011 Jun; 11(6):14-6. PubMed ID: 21678206
    [No Abstract]   [Full Text] [Related]  

  • 5. Sexual transmission risk perceptions and behavioural correlates of HIV concentrations in semen.
    Kalichman SC; Rompa D; Cage M; Austin J; Luke W; Barnett T; Tharnish P; Mowrey J; Schinazi RF
    AIDS Care; 2002 Jun; 14(3):343-9. PubMed ID: 12042080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to Open Peer Commentaries on "Relative versus absolute standards for everyday risk in adolescent HIV prevention trials: expanding the debate".
    Snyder J; Miller CL; Gray G
    Am J Bioeth; 2011 Jun; 11(6):W1-3. PubMed ID: 21678202
    [No Abstract]   [Full Text] [Related]  

  • 7. Time to take stock in HIV/AIDS prevention.
    Kalichman SC
    AIDS Behav; 2008 May; 12(3):333-4. PubMed ID: 18360742
    [No Abstract]   [Full Text] [Related]  

  • 8. (Un)risky business: adolescents and HIV prevention trials.
    Philpott S
    Am J Bioeth; 2011 Jun; 11(6):17-9. PubMed ID: 21678207
    [No Abstract]   [Full Text] [Related]  

  • 9. Barriers to participating in an HIV vaccine trial: a systematic review.
    Mills E; Cooper C; Guyatt G; Gilchrist A; Rachlis B; Sulway C; Wilson K
    AIDS; 2004 Nov; 18(17):2235-42. PubMed ID: 15577535
    [No Abstract]   [Full Text] [Related]  

  • 10. Potential pitfalls on the road to an effective HIV vaccine.
    Schwartz DH
    Immunol Today; 1994 Feb; 15(2):54-7. PubMed ID: 7908803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparations for AIDS vaccine trials. Recruitment and retention of in- and out-of-treatment injection drug users.
    Woody GE; Metzger D; Mulvaney F
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S197-9. PubMed ID: 7865300
    [No Abstract]   [Full Text] [Related]  

  • 12. HIV vaccines for injection drug users in the context of a comprehensive prevention agenda.
    Vlahov D
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S3-6. PubMed ID: 7865324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal risk remains an open question.
    Binik A; Weijer C; Sheehan M
    Am J Bioeth; 2011 Jun; 11(6):25-7. PubMed ID: 21678212
    [No Abstract]   [Full Text] [Related]  

  • 14. AIDS complacency leads back to risky behavior.
    AIDS Alert; 1999 Nov; 14(11):127-8. PubMed ID: 11366980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential role of the HIV-1 immunogen (Remune) as a therapeutic vaccine in the treatment of HIV infection.
    Fernández-Cruz E; Navarro J; Rodríguez-Sainz C; Gil J; Moreno S; González-Lahoz J; Carbone J
    Expert Rev Vaccines; 2003 Dec; 2(6):739-52. PubMed ID: 14711358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale for the testing and use of a partially effective HIV vaccine.
    Vermund SH
    AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S321-3. PubMed ID: 9814960
    [No Abstract]   [Full Text] [Related]  

  • 17. Why we don't need a relative risk standard for adolescent HIV vaccine trials in South Africa.
    Slack CM
    Am J Bioeth; 2011 Jun; 11(6):21-2. PubMed ID: 21678209
    [No Abstract]   [Full Text] [Related]  

  • 18. [First clinical study in Germany. Vaccination against HIV coming soon?].
    Kurth R
    MMW Fortschr Med; 2003 Nov; 145(46):16. PubMed ID: 14699826
    [No Abstract]   [Full Text] [Related]  

  • 19. Uniqueness, exploitation, and relative risk standards in adolescent research.
    Malek J
    Am J Bioeth; 2011 Jun; 11(6):23-5. PubMed ID: 21678211
    [No Abstract]   [Full Text] [Related]  

  • 20. [Vaccinations of HIV-infected travelers].
    Couzigou C; Voyer C; Shaghaghi CK; Bourée P; Vittecoq D
    Med Mal Infect; 2009 Jan; 39(1):21-8. PubMed ID: 18723304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.